CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We are very excited to launch our new website! Please take a few moments to click around and explore...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...